Efficacy and safety of once-weekly somatrogon in adults with growth hormone deficiency: a randomized phase 3 study.

Saved in:
Bibliographic Details
Title: Efficacy and safety of once-weekly somatrogon in adults with growth hormone deficiency: a randomized phase 3 study.
Authors: Fleseriu M; Pituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health & Science University, Portland, OR, USA. fleseriu@ohsu.edu., Biller BMK; Neuroendocrine & Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, MA, USA., Webb SM; Department of Medicine, Univ Autonoma Barcelona; Research Center for Pituitary Diseases, Recerca Sant Pau (IIB-Sant Pau) and CIBERER, Unit 747, ISCIII, Madrid, Spain.; Department of Endocrinology, Hospital S Pau, Barcelona, Spain., Strasburger CJ; Department of Endocrinology and Metabolism, Charité-Universitätsmedizin Berlin, Berlin, Germany., Georgescu CE; Department of Endocrinology, Endocrinology Clinical Unit, Iuliu Hatieganu University of Medicine and Pharmacy Cluj, Cluj County Emergency Hospital, Cluj-Napoca, Romania., Bidlingmaier M; Endocrine Laboratory, Medizinische Klinik und Poliklinik IV, LMU Klinikum, Munich, Germany., Wang C; Clinical and Translational Science Institute and Division of Endocrinology, Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, USA., Baciu I; C.I. Parhon National Institute of Endocrinology, C. Davila University of Medicine and Pharmacy, Bucharest, Romania., Casanueva FF; Department of Medicine, CIBER de Fisiopatología Obesidad y Nutricion, Instituto Salud Carlos III, Santiago de Compostela University, Complejo Hospitalario Universitario de Santiago (IDIS), Santiago de Compostela, CB06/03, Spain., Gilis-Januszewska A; Department of Endocrinology, Medical College, Jagiellonian University, Krakow, Poland., Hart G; OPKO Biologics Ltd, Kiryat Gat, Israel., Manners A; OPKO Pharmaceuticals, LLC., a subsidiary of OPKO Health, Inc., Miami, FL, USA., Choe J; OPKO Health Inc, Miami, FL, USA., Bar-Ilan A; OPKO Biologics Ltd, Kiryat Gat, Israel., Carlsson M; Pfizer Inc, New York, NY, USA., Torre D; Pfizer SRL, Rome, Italy., Taylor CT; Pfizer Inc, New York, NY, USA., Yuen KCJ; Departments of Neuroendocrinology and Neurology, Barrow Neurological Institute, Barrow Pituitary Center, University of Arizona College of Medicine and Creighton University School of Medicine, Phoenix, Arizona, 85013, USA.
Source: Pituitary [Pituitary] 2026 Mar 25; Vol. 29 (2). Date of Electronic Publication: 2026 Mar 25.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
Journal Info: Publisher: Kluwer Academic Publishers Country of Publication: United States NLM ID: 9814578 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-7403 (Electronic) Linking ISSN: 1386341X NLM ISO Abbreviation: Pituitary Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1573-7403
DOI:10.1007/s11102-026-01661-1